白瑾,谢鹏昕,李延广,井然,李宗师,周公哺,刘书旺

• 1:北京大学第三医院心内科血管医学研究所血管稳态与重构全国重点实验室
• 2:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所

摘要(Abstract)：

目的 本研究旨在分析影响接受射频消融治疗的心房颤动（房颤）患者术后发生主要不良心血管事件（MACE）的因素，并分析比较不同年龄房颤患者接受射频消融治疗的预后差异。方法 本研究持续入组2021年1月至2023年3月于北京大学第三医院接受射频消融治疗的房颤患者。通过医院住院系统收集患者一般数据。MACE收集通过门诊随访和电话随访。进一步按年龄将患者分为3组：组1(<65岁)、组2(65～75岁)、组3(>75岁)，分析不同年龄患者的预后差异。在本研究中，MACE定义为心血管死亡、全因死亡、因心力衰竭再入院、急性冠状动脉综合征、脑卒中。结果 本研究共纳入431例患者，平均年龄为（66.17±12.22）岁。男259例（60.09%）,CHA2DS2-VASc评分为（1.79±1.30）分。中位随访期为16.0(11.3,21.3)个月，在此期间发生MACE 28例（6.50%），其中多为急性冠状动脉综合征和脑卒中。采用LASSO回归法筛选变量，构建LASSO-Cox回归模型后，年龄（HR 1.06,95%CI 1.02～1.10,P=0.006）和肥厚型心肌病（HR 3.70,95%CI 1.27～8.68,P=0.008）是房颤射频消融治疗后出现MACE的独立预测因素。年龄分组结果，组1患者相比老年房颤患者具有显著更好的预后（与组2比较P=0.030；与组3比较P=0.021）。房颤患者（>75岁）接受射频消融治疗后的长期预后与65～75岁患者相似（P=0.600）。结论 年龄和肥厚型心肌病是房颤患者接受射频消融治疗后MACE的独立危险因素。非老年患者的预后显著优于老年患者（≥65岁），>75岁患者的预后与65～75岁患者相似。

关键词(KeyWords)： 心房颤动;主要不良心血管事件;射频消融;年龄;肥厚型心肌病

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（82300349）

作者(Author): 白瑾,谢鹏昕,李延广,井然,李宗师,周公哺,刘书旺

参考文献(References)：

• [1]Hindricks G,Potpara T,Dagres N,et al.2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for CardioThoracic Surgery(EACTS):the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC)developed with the special contribution of the European Heart Rhythm Association(EHRA)of the ESC[J].Eur Heart J,2021,42(5):373-498.DOI:10.1093/eurheartj/ehaa612.
• [2]Furie KL,Jayaraman MV 2018 guidelines for the early management of patients with acute ischemic stroke[J].Stroke,2018,49(3):509-510.DOI:10.1161/STROKEAHA.118.020176.
• [3]Joglar JA,Chung MK,Armbruster AL,et al.2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].J Am Coll Cardiol,2024,83(1):109-279.DOI:10.1016/j.jacc.2023.08.017.
• [4]Turagam MK,Musikantow D,Whang W,et al.Assessment of catheter ablation or antiarrhythmic drugs for first-line therapy of atrial fibrillation:a meta-analysis of randomized clinical trials[J].JAMA Cardiol,2021,6(6):697-705.DOI:10.1001/jamacardio.2021.0852.
• [5]Monahan KH,Bunch TJ,Mark DB,et al.Influence of atrial fibrillation type on outcomes of ablation vs.drug therapy:results from CABANA[J].Europace,2022,24(9):1430-1440.DOI:10.1093/europace/euac05 5.
• [6]Andrade JG,Deyell MW,Macle L,et al.Progression of atrial fibrillation after cryoablation or drug therapy[J].N Engl J Med,2023,388(2):105-116.DOI:10.1056/NEJMoa2212540.
• [7]Akerstr?m F,Hutter J,Charitakis E,et al.Association between catheter ablation of atrial fibrillation and mortality or stroke[J].Heart,2024,110(3):163-169.DOI:10.1136/heartjnl-2023-322883.
• [8]Di Biase L,Mohanty P,Mohanty S,et al.Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device:results from the aatac multicenter randomized trial[J].Circulation,2016,133(17):1637-1644.DOI:10.1161/CIRCULATIONAHA.115.019406.
• [9]Zhang Z,Zheng Y,He W,et al.Efficacy of catheter ablation for atrial fibrillation in heart failure:a meta-analysis of randomized controlled trials[J].ESC Heart Fail,2024,11(5):2684-2693.DOI:10.1002/ehf2.14814.
• [10]Chang CH,Lin JW,Chiu FC,et al.Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality:a nationwide cohort study and propensity score analysis[J].Circ Arrhythm Electrophysiol,2014,7(1):76-82.DOI:10.1161/CIRCEP.113.000597.
• [11]Jacobs V,May HT,Bair TL,et al.The impact of risk score(CHADS_2 versus CHA_2DS_2-VASc)on long-term outcomes after atrial fibrillation ablation[J].Heart Rhythm,2015,12(4):681-686.DOI:10.1016/j.hrthm.2014.12.034.
• [12]Ngo L,Woodman R,Denman R,et al.Longitudinal risk of death,hospitalizations for atrial fibrillation,and cardiovascular events following catheter ablation of atrial fibrillation:a cohort study[J].Eur Heart J Qual Care Clin Outcomes,2023,9(2):150-160.DOI:10.1093/ehjqcco/qcac024.
• [13]Zolotarova TV,Brynza MS,Volkov DY,et al.Predictors of atrial fibrillation recurrence after radiofrequency ablation in patients with chronic heart failure[J].Wiad Lek,2021,74(8):1850-1855.
• [14]Masuda M,Fujita M,Iida O,et al.Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation[J].Int J Cardiol,2018,257:97-101.DOI:10.1016/j.ijcard.2017.12.089.
• [15]Costa FM,Ferreira AM,Oliveira S,et al.Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation[J].Int J Cardiol,2015,184:56-61.DOI:10.1016/j.ijcard.2015.01.060.
• [16]Bahnson TD,Giczewska A,Mark DB,et al.Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation:results from the CABANA trial[J].Circulation,2022,145(11):796-804.DOI:10.1161/CIRCULATIONAHA.121.055297.
• [17]Moser JM,Willems S,Andresen D,et al.Complication rates of catheter ablation of atrial fibrillation in patients aged≥75 years versus<75 years-results from the german ablation registry[J].J Cardiovasc Electrophysiol,2017,28(3):258-265.DOI:10.1111/jce.13142.
• [18]Su X,Du X,Lu SX,et al.Catheter ablation for atrial fibrillation is associated with reduced risk of mortality in the elderly:a prospective cohort study and propensity score analysis[J].J Geriatr Cardiol,2020,17(12):740-749.DOI:10.11909/j.issn.1671-5411.2020.12.008.
• [19]Blandino A,Toso E,Scaglione M,et al.Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation[J].J Cardiovasc Electrophysiol,2013,24(7):731-738.DOI:10.1111/jce.12126.
• [20]Mikhaylov EN,Szili-Torok T,Lebedev DS.Percutaneous interventions in elderly patients with atrial fibrillation:left atrial ablation and left atrial appendage occlusion[J].J Geriatr Cardiol,2017,14(9):541-546.DOI:10.11909/j.issn.1671-5411.2017.09.009.
• [21]T?nnesen J,Ruwald MH,Pallisgaard J,et al.Lower recurrence rates of atrial fibrillation and mace events after early compared to late ablation:a danish nationwide register study[J].J Am Heart Assoc,2024,13(7):e032722.DOI:10.1161/JAHA.123.032722.
• [22]Maron BJ,Desai MY,Nishimura RA,et al.Management of hypertrophic cardiomyopathy:JACC state-of-the-art review[J].J Am Coll Cardiol,2022,79(4):390-414.DOI:10.1016/j.jacc.2021.11.021.
• [23]Zegkos T,Efthimiadis GK,Parcharidou DG,et al.Atrial fibrillation in hypertrophic cardiomyopathy:a turning point towards increased morbidity and mortality[J].Hellenic J Cardiol,2017,58(5):331-339.DOI:10.1016/j.hjc.2017.01.027.
• [24]Garg L,Gupta M,Sabzwari SRA,et al.Atrial fibrillation in hypertrophic cardiomyopathy:prevalence,clinical impact,and management[J].Heart Fail Rev,2019,24(2):189-197.DOI:10.1007/s10741-018-9752-6.
• [25]Chung MK,Refaat M,Shen WK,et al.Atrial fibrillation:JACC council perspectives[J].J Am Coll Cardiol,2020,75(14):1689-1713.DOI:10.1016/j.jacc.2020.02.025.
• [26]Latif A,Ahmad S,Ahsan MJ,et al.Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy:a proportional meta-analysis and systematic review of single-arm studies[J].Heart Rhythm O2,2023,4(4):258-267.DOI:10.1016/j.hroo.2023.01.002.
• [27]Buckley BJR,Harrison SL,Gupta D,et al.Atrial fibrillation in patients with cardiomyopathy:prevalence and clinical outcomes from real-world data[J].J Am Heart Assoc,2021,10(23):e021970.DOI:10.1161/JAHA.121.021970.